비교리스트

 카트 문의
시장보고서
상품코드
1526094

세계의 철제 정맥내 투여 시장

Intravenous (IV) Iron Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 354 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

철제 정맥내 투여 세계 시장은 2030년까지 48억 달러에 이를 전망

2023년에 29억 달러로 추정되는 철제 정맥내 투여 세계 시장은 분석 기간인 2023-2030년에 CAGR 7.3%로 성장하여 2030년에는 48억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Ferric Carboxymaltos은 CAGR 7.6%를 나타내고, 분석 기간 종료시에는 23억 달러에 이를 것으로 예상됩니다. Iron Dextran 부문의 성장률은 분석 기간중 CAGR 6.6%로 추정됩니다.

미국 시장은 10억 달러로 추정, 중국은 CAGR 10.8%로 성장 예측

미국의 철제 정맥내 투여 시장은 2023년에 10억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 6억 5,840만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2023-2030년간 CAGR은 10.8%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.8%와 6.3%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.8%를 나타낼 전망입니다.

세계 철제 정맥내 투여 시장 - 주요 동향 및 촉진요인 요약

철제 정맥내 투여는 주로 철결핍성 빈혈(건강한 적혈구를 생성하기에 충분한 철분이 체내에 부족한 상태)을 치료하기 위해 사용되는 필수 치료법입니다. 혈류로 직접 투여하기 때문에 특히 경구용 철분 보충제를 복용할 수 없거나 충분히 흡수하지 못하는 환자들에게 신속하고 효율적인 흡수를 가능하게 합니다. 정맥 내 철분 투여는 만성 신장 질환, 염증성 장 질환, 심부전, 화학 요법을 받고 있는 환자에게 매우 중요합니다. 수크로오스 철, 카르복시말토오스 철, 덱스트런 철 등 다양한 제형이 개발되어 효능과 안전성을 최적화하고 알레르기 반응 및 아나필락시스와 같은 잠재적 부작용을 최소화하고 있습니다. 이러한 제형의 발전으로 1회 투여량을 늘릴 수 있게 되어 환자의 순응도와 치료 결과를 개선할 수 있게 되었습니다.

철제 정맥내 투여 시장의 성장은 제형 기술의 발전, 정맥 내 철분 요법의 적응증 확대, 정맥 내 철분 요법의 이점에 대한 의료 서비스 제공업체와 환자의 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 고용량 및 신속한 투여를 가능하게 하는 보다 안전한 새로운 제제의 개발은 정맥 내 철분 요법의 매력을 크게 증가시키고 있습니다. 또한, 만성 신장 질환, 암, 심부전 등 철분 결핍과 관련이 있는 만성 질환의 유병률이 증가함에 따라 효과적인 철분 보충에 대한 수요가 증가하고 있습니다. 또한, 진단 능력의 향상과 함께 이러한 질환을 관리하기 위한 철분 정맥 주사의 사용이 확대되고 있는 것도 시장 성장에 기여하고 있습니다. 또한, 보다 효율적이고 환자 친화적인 치료법을 추구하는 헬스케어 트렌드와 맞물려 외래 치료 및 입원 기간 단축에 대한 중요성이 강조되면서 철제 정맥내 투여 도입에 영향을 미치고 있습니다.

따라서 세계 철제 정맥내 투여 시장은 고령화 인구 증가, 평균 수명 증가, CKD 발병률 증가, ESRD 환자 수 증가 등에 힘입어 꾸준한 성장세를 보일 것으로 예측됩니다. 의료비 증가, 도시화 진행, 의료 기관에서 정한 유리한 가이드라인 등이 성장을 가속하는 다른 요인으로는 의료비 증가, 도시화 진행 등이 있습니다. 또한, 기존 덱스트런 제제에서 비덱스트런 제제로 수요 전환이 빠르게 진행되고 있습니다. 비덱스트런 기반 정맥주사용 철분제는 덱스트런 기반 정맥주사용 철분제에 비해 단시간에 고용량 철분제를 투여할 수 있다는 장점이 있습니다. 또한, 비덱스트란 기반 약물은 기존 철분 요법과 관련된 안전성, 내약성, 용량, 순응도 등 다양한 문제를 해결할 수 있습니다.

조사 대상 기업 예(주요 33개사)

  • AbbVie Inc(AbbVie)
  • Akebia Therapeutics, Inc.
  • American Regent, Inc.
  • Covis Pharma GmbH.
  • Daiichi Sankyo Company, Ltd.
  • Galenica Group
  • Iron4u Aps
  • NIPPON SHINYAKU CO., LTD.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi S.A.
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.08.09

Global Intravenous (IV) Iron Drugs Market to Reach US$4.8 Billion by 2030

The global market for Intravenous (IV) Iron Drugs estimated at US$2.9 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Iron Dextran segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$1.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Intravenous (IV) Iron Drugs Market - Key Trends & Drivers Summarized

Intravenous (IV) iron drugs are essential treatments used primarily for addressing iron deficiency anemia, a condition where the body lacks sufficient iron to produce healthy red blood cells. These drugs are administered directly into the bloodstream, allowing for quick and efficient absorption, especially in patients who cannot tolerate or adequately absorb oral iron supplements. IV iron therapy is crucial for patients with chronic kidney disease, inflammatory bowel disease, heart failure, and those undergoing chemotherapy, as these conditions often result in significant iron loss or hinder the absorption of iron. Various formulations of IV iron, such as iron sucrose, ferric carboxymaltose, and iron dextran, have been developed to optimize their efficacy and safety, minimizing potential side effects like allergic reactions or anaphylaxis. The advancement in these formulations has made it possible to deliver higher doses in a single session, improving patient compliance and outcomes.

The growth in the intravenous (IV) iron drugs market is driven by several factors, including technological advancements in drug formulations, expanding indications for IV iron therapy, and increasing awareness among healthcare providers and patients about the benefits of IV iron. The development of newer, safer formulations that allow for higher doses and quicker administration has significantly enhanced the appeal of IV iron therapies. Additionally, the rising prevalence of chronic diseases such as chronic kidney disease, cancer, and heart failure, which are often associated with iron deficiency, has created a higher demand for effective iron supplementation methods. The expanding applications of IV iron in managing these conditions, coupled with improved diagnostic capabilities, have also contributed to market growth. Furthermore, the growing emphasis on outpatient care and the reduction of hospital stay durations are influencing the adoption of IV iron treatments, as they align with the broader healthcare trend towards more efficient and patient-friendly therapeutic options.

The global intravenous iron drugs market, therefore, is forecast to witness a steady growth, driven by the increase in aging population, growing life expectancy rate, growing incidence of CKD, and rise in number of ESRD patients. Other factors driving growth include increasing healthcare expenditure, rising urbanization, and favorable guidelines laid down by healthcare organizations. Furthermore, the market is also witnessing rapid transition in terms of demand from traditional dextran to non-dextran intravenous iron drugs. Non-dextran intravenous iron drug offer higher advantageous over dextran intravenous iron drugs in terms of delivering higher doses of infusing iron in a shorter time period. Additionally, the non-dextran based drugs are capable of addressing various challenges, such as safety, intolerance, dosing, and compliance associated with traditional iron therapies.

Select Competitors (Total 33 Featured) -

  • AbbVie Inc (AbbVie)
  • Akebia Therapeutics, Inc.
  • American Regent, Inc.
  • Covis Pharma GmbH.
  • Daiichi Sankyo Company, Ltd.
  • Galenica Group
  • Iron4u Aps
  • NIPPON SHINYAKU CO., LTD.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi S.A.
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Iron Deficiency Anemia (IDA) - A Major Global Health Concern
    • Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN)
    • Global Economic Update
    • Competitive Landscape
    • Intravenous (IV) Iron Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Global Intravenous Iron Drugs Market Driven by Rising Incidence of CKD and Cancer
    • Ferric CarboxyMaltose Dominates the Global Intravenous Iron Drugs Market
    • CKD Leads the Application Segment, Cancer Expected to Witness Fastest Growth
    • North America and Europe Hold Major Share, Asia-Pacific Witnesses Rapid Growth
    • Low- and Mid-income Countries Present Lucrative Penetration Opportunities for IV Iron Drugs
    • The Target Patient Populations
    • Leading Intravenous Iron Drugs Globally
    • Leading IV Iron Drugs Available in the Market
    • Leading Intravenous Iron Drugs: In a Nutshell
    • Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally
    • Venofer(R)
    • Feraheme
    • Gluconate (Ferrlecit(R) and Nulecit)
    • Dextran
    • Monoferric
    • Triferic AVNU
    • INFeD
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (Iv) Iron Drugs
    • Dialysis Patients - A Major Market for Intravenous Iron Supplements
    • Global Dialysis Patient Population Breakdown by Geographic Region/Country (2019 and 2024)
    • Ageing Population Drives Demand for IV Iron Drugs
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Incidence of Cancer and the Associated Anemia Drives the Demand for Intravenous Iron Drugs
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Rising Incidence of Diabetes to Propel the Market for Intravenous Iron Drugs
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030, and 2045
    • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
    • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
    • Comparison of Ferrous Salts with IV Iron Therapy
    • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
    • New Study Demonstrates IV Iron to Improve Long-term Outcomes in Heart Failure Patients
    • Incidence of Heart Failure (In 000s) in the U.S. by Gender for the Year 2022
    • Correction of IDA in Pregnancy Signals Opportunities
    • Women's Health - A Key Growth Opportunity
    • Perioperative and Postoperative Anemia - A Niche Market Beckons
    • Adverse Reactions of IV Iron Preparations Raise Concerns
    • Dosing Limitations Plague IV Iron Market
    • Select Therapeutic Areas and the Required Iron Doses
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Ferric Carboxymaltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Iron Dextran by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Intravenous (IV) Iron Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제